Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation

Internal and Emergency Medicine

Volumn 10, Issue 5, 2015, Pages 555-560

  Arnao, Valentina ^a   Agnelli, Giancarlo ^b   Paciaroni, Maurizio ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Medicine; Non valvular atrial fibrillation; Secondary prevention; Stroke

Indexed keywords

ANTICOAGULANT AGENT;

ATRIAL FIBRILLATION; COMPLICATION; HUMAN; ISCHEMIC ATTACK, TRANSIENT; ORAL DRUG ADMINISTRATION; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; ISCHEMIC ATTACK, TRANSIENT; STROKE;

EID: 84937977287     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-015-1226-4     Document Type: Review

References (31)

1. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983–988
2. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R et al (2005) Contribution of atrial fibrillation to incidence and outcome of ischemic stroke. Results from a population study. Stroke 36(6):1115–1119
3. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146(12):857–867
4. Hankey GJ, Eikelboom JW (2010) Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol 9(3):273–284
5. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators (2012) Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 11(4):315–322
6. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC, ARISTOTLE Committees and Investigators (2012) Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 11(6):503–511
7. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50(7):743–753
8. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151
10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM (2011) ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891
11. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, ENGAGE AF-TIMI 48 Investigators (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104
12. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W (2013) Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 126(20):2381–2391
13. Sardar P, Chatterjee S, Wu WC, Lichstein E, Ghosh J, Aikat S, Mukherjee D (2013) New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLoS ONE 8(10):e77694
14. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P (2012) Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 43(12):3298–3304
15. Micheli S, Agnelli G, Caso V, Alberti A, Palmerini F, Venti M, Paciaroni M (2012) Acute myocardial infarction and heart failure in acute stroke patients: frequency and influence on clinical outcome. J Neurol 259(1):106–110
16. Rubboli A, Oldgren J, Marìn F, Lip G (2013) Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard? Intern Emerg Med 8:673–680
17. Karjalainen PP, Porela P, Ylitalo A et al (2007) Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 28:726–732
18. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S (2013) Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 127(5):634–640
19. Mega JL, Braunwald Wiviott SD, Bassand JP, Bhatt Bode et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9–19
20. Rubboli A, Verheugt FW (2008) Antithrombotic treatment for patients on oral anticoagulation undergoing coronary stenting. A review of the available evidence and practical suggestions for the clinician. Int J Cardiol 123:234–239
21. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al (2006) Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114(7):e257–e354
22. Paciaroni M, Agnelli G, Ageno W, Caso V, Corea F, Lanari A, Alberti A, Previdi P, Fedele M, Manina G, Vedovati C, Venti M, Billeci AM, Batta M, Galli L, Silvestrelli G (2010) Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. Atherosclerosis 212(2):564–566
23. Violi F, Lip GYH, Basili S (2012) Peripheral artery disease and atrial fibrillation: a potentially dangerous combination. Intern Emerg Med 7(3):213–218
24. Benbir Gulcin, Uluduz Derya, Ince Birsen, Bozluolcay Melda (2007) Atherothrombotic ischemic stroke in patients with atrial fibrillation. Clin Neurol Neurosurg 109:485–490
25. Cote R, Battista RN, Abramowicz M et al (1995) Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Ann Intern Med 123:649–655
26. Paciaroni M, Bogousslavsky J (2014) Antithrombotic therapy in carotid artery stenosis: an update. Eur Neurol 73(1–2):51–56
27. Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lunari A, Caso V, Micheli S, Bertolani L, Venti M, Palmerini F, Biagini S, Comi G, Previdi P, Silvestrelli G (2008) Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke 39:2249–2256
28. De Schryver EL, Algra A, Kappelle LJ, van Gijn J, Koudstaal PJ (2012) Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database Syst Rev 9:CD001342
29. http://www.clinicaltrials.gov. Accessed 18 Dec 2014
30. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T (2013) A specific antidote for dabigatran: functional and structural characterization. Blood 121(18):3554–3562. doi:10.1182/blood-2012-11-468207
31. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19(4):446–451